The global Multiple Sclerosis (MS) Drugs market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Multiple Sclerosis (MS) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Multiple Sclerosis (MS) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Multiple Sclerosis (MS) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key manufacturers of Multiple Sclerosis (MS) Drugs include Bayer AG, Bayhill Therapeutics, Biogen Idec, Cinnagen, Daiichi Sankyo, Eli Lilly, Fast Forward Llc, Antisense Therapeutics and Apitope, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes:
This report presents an overview of global market for Multiple Sclerosis (MS) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Multiple Sclerosis (MS) Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Multiple Sclerosis (MS) Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Multiple Sclerosis (MS) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Multiple Sclerosis (MS) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Multiple Sclerosis (MS) Drugs sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bayer AG, Bayhill Therapeutics, Biogen Idec, Cinnagen, Daiichi Sankyo, Eli Lilly, Fast Forward Llc, Antisense Therapeutics and Apitope, etc.
By Company
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
Segment by Type
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Segment by Application
RRMS
SPMS
PPMS
PRMS
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Multiple Sclerosis (MS) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Multiple Sclerosis (MS) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Multiple Sclerosis (MS) Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.3 Novantrone (Mitoxantrone)
1.2.4 Gilenya (Fingolimod, Fty720)
1.2.5 Aubagio (Teriflunomide)
1.2.6 Tecfidera (Dimethyl Fumarate)
1.2.7 Firategrast (Sb683699, T-0047)
1.2.8 Siponimod (Baf312)
1.2.9 Others
1.3 Market by Application
1.3.1 Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Multiple Sclerosis (MS) Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region
2.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2018-2023)
2.2.3 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2024-2029)
2.2.4 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2018-2029)
2.3 Global Multiple Sclerosis (MS) Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global Multiple Sclerosis (MS) Drugs Sales by Region
2.4.1 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Multiple Sclerosis (MS) Drugs Sales by Region (2018-2023)
2.4.3 Global Multiple Sclerosis (MS) Drugs Sales by Region (2024-2029)
2.4.4 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers
3.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers (2018-2023)
3.1.2 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Multiple Sclerosis (MS) Drugs in 2022
3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers
3.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Multiple Sclerosis (MS) Drugs Revenue in 2022
3.3 Global Key Players of Multiple Sclerosis (MS) Drugs, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Multiple Sclerosis (MS) Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Multiple Sclerosis (MS) Drugs Sales by Type
4.1.1 Global Multiple Sclerosis (MS) Drugs Historical Sales by Type (2018-2023)
4.1.2 Global Multiple Sclerosis (MS) Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2018-2029)
4.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type
4.2.1 Global Multiple Sclerosis (MS) Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global Multiple Sclerosis (MS) Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Multiple Sclerosis (MS) Drugs Price by Type
4.3.1 Global Multiple Sclerosis (MS) Drugs Price by Type (2018-2023)
4.3.2 Global Multiple Sclerosis (MS) Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Multiple Sclerosis (MS) Drugs Sales by Application
5.1.1 Global Multiple Sclerosis (MS) Drugs Historical Sales by Application (2018-2023)
5.1.2 Global Multiple Sclerosis (MS) Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2018-2029)
5.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application
5.2.1 Global Multiple Sclerosis (MS) Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global Multiple Sclerosis (MS) Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Multiple Sclerosis (MS) Drugs Price by Application
5.3.1 Global Multiple Sclerosis (MS) Drugs Price by Application (2018-2023)
5.3.2 Global Multiple Sclerosis (MS) Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Multiple Sclerosis (MS) Drugs Market Size by Type
6.1.1 US & Canada Multiple Sclerosis (MS) Drugs Sales by Type (2018-2029)
6.1.2 US & Canada Multiple Sclerosis (MS) Drugs Revenue by Type (2018-2029)
6.2 US & Canada Multiple Sclerosis (MS) Drugs Market Size by Application
6.2.1 US & Canada Multiple Sclerosis (MS) Drugs Sales by Application (2018-2029)
6.2.2 US & Canada Multiple Sclerosis (MS) Drugs Revenue by Application (2018-2029)
6.3 US & Canada Multiple Sclerosis (MS) Drugs Market Size by Country
6.3.1 US & Canada Multiple Sclerosis (MS) Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Multiple Sclerosis (MS) Drugs Sales by Country (2018-2029)
6.3.3 US & Canada Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Multiple Sclerosis (MS) Drugs Market Size by Type
7.1.1 Europe Multiple Sclerosis (MS) Drugs Sales by Type (2018-2029)
7.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Type (2018-2029)
7.2 Europe Multiple Sclerosis (MS) Drugs Market Size by Application
7.2.1 Europe Multiple Sclerosis (MS) Drugs Sales by Application (2018-2029)
7.2.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Application (2018-2029)
7.3 Europe Multiple Sclerosis (MS) Drugs Market Size by Country
7.3.1 Europe Multiple Sclerosis (MS) Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2018-2029)
7.3.3 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Multiple Sclerosis (MS) Drugs Market Size
8.1.1 China Multiple Sclerosis (MS) Drugs Sales (2018-2029)
8.1.2 China Multiple Sclerosis (MS) Drugs Revenue (2018-2029)
8.2 China Multiple Sclerosis (MS) Drugs Market Size by Application
8.2.1 China Multiple Sclerosis (MS) Drugs Sales by Application (2018-2029)
8.2.2 China Multiple Sclerosis (MS) Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Multiple Sclerosis (MS) Drugs Market Size by Type
9.1.1 Asia Multiple Sclerosis (MS) Drugs Sales by Type (2018-2029)
9.1.2 Asia Multiple Sclerosis (MS) Drugs Revenue by Type (2018-2029)
9.2 Asia Multiple Sclerosis (MS) Drugs Market Size by Application
9.2.1 Asia Multiple Sclerosis (MS) Drugs Sales by Application (2018-2029)
9.2.2 Asia Multiple Sclerosis (MS) Drugs Revenue by Application (2018-2029)
9.3 Asia Multiple Sclerosis (MS) Drugs Sales by Region
9.3.1 Asia Multiple Sclerosis (MS) Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Multiple Sclerosis (MS) Drugs Revenue by Region (2018-2029)
9.3.3 Asia Multiple Sclerosis (MS) Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bayer AG
11.1.1 Bayer AG Company Information
11.1.2 Bayer AG Overview
11.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer AG Recent Developments
11.2 Bayhill Therapeutics
11.2.1 Bayhill Therapeutics Company Information
11.2.2 Bayhill Therapeutics Overview
11.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayhill Therapeutics Recent Developments
11.3 Biogen Idec
11.3.1 Biogen Idec Company Information
11.3.2 Biogen Idec Overview
11.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Biogen Idec Recent Developments
11.4 Cinnagen
11.4.1 Cinnagen Company Information
11.4.2 Cinnagen Overview
11.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Cinnagen Recent Developments
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Information
11.5.2 Daiichi Sankyo Overview
11.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Daiichi Sankyo Recent Developments
11.6 Eli Lilly
11.6.1 Eli Lilly Company Information
11.6.2 Eli Lilly Overview
11.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Eli Lilly Recent Developments
11.7 Fast Forward Llc
11.7.1 Fast Forward Llc Company Information
11.7.2 Fast Forward Llc Overview
11.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Fast Forward Llc Recent Developments
11.8 Antisense Therapeutics
11.8.1 Antisense Therapeutics Company Information
11.8.2 Antisense Therapeutics Overview
11.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Antisense Therapeutics Recent Developments
11.9 Apitope
11.9.1 Apitope Company Information
11.9.2 Apitope Overview
11.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Apitope Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Apitope Recent Developments
11.10 Five Prime Therapeutics
11.10.1 Five Prime Therapeutics Company Information
11.10.2 Five Prime Therapeutics Overview
11.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Five Prime Therapeutics Recent Developments
11.11 Genmab
11.11.1 Genmab Company Information
11.11.2 Genmab Overview
11.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 Genmab Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Genmab Recent Developments
11.12 Artielle Immunotherapeutics
11.12.1 Artielle Immunotherapeutics Company Information
11.12.2 Artielle Immunotherapeutics Overview
11.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Artielle Immunotherapeutics Recent Developments
11.13 Genzyme
11.13.1 Genzyme Company Information
11.13.2 Genzyme Overview
11.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.13.4 Genzyme Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Genzyme Recent Developments
11.14 Glaxosmithkline
11.14.1 Glaxosmithkline Company Information
11.14.2 Glaxosmithkline Overview
11.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Glaxosmithkline Recent Developments
11.15 Gw Pharmaceuticals
11.15.1 Gw Pharmaceuticals Company Information
11.15.2 Gw Pharmaceuticals Overview
11.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Gw Pharmaceuticals Recent Developments
11.16 Innate Immunotherapeutics
11.16.1 Innate Immunotherapeutics Company Information
11.16.2 Innate Immunotherapeutics Overview
11.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Innate Immunotherapeutics Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Multiple Sclerosis (MS) Drugs Industry Chain Analysis
12.2 Multiple Sclerosis (MS) Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Multiple Sclerosis (MS) Drugs Production Mode & Process
12.4 Multiple Sclerosis (MS) Drugs Sales and Marketing
12.4.1 Multiple Sclerosis (MS) Drugs Sales Channels
12.4.2 Multiple Sclerosis (MS) Drugs Distributors
12.5 Multiple Sclerosis (MS) Drugs Customers
13 Market Dynamics
13.1 Multiple Sclerosis (MS) Drugs Industry Trends
13.2 Multiple Sclerosis (MS) Drugs Market Drivers
13.3 Multiple Sclerosis (MS) Drugs Market Challenges
13.4 Multiple Sclerosis (MS) Drugs Market Restraints
14 Key Findings in The Global Multiple Sclerosis (MS) Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
听
听
*If Applicable.